詳細ガイド 近日公開
Insomnia Severity Index Calculatorの包括的な教育ガイドを準備中です。ステップバイステップの解説、数式、実例、専門家のヒントをお届けしますので、もうしばらくお待ちください。
The Insomnia Severity Index (ISI) Calculator scores the seven-item self-report measure of insomnia severity developed by Charles Morin at Universite Laval. The ISI is the most widely used outcome measure in insomnia treatment research and clinical practice, providing a reliable and valid assessment of the nature, severity, and daytime impact of insomnia symptoms over the past two weeks. Insomnia is the most prevalent sleep disorder, affecting approximately 30 percent of adults at any given time with acute symptoms and 10 percent meeting criteria for chronic insomnia disorder (symptoms persisting three or more months with daytime impairment). The economic burden of insomnia in the United States exceeds $63 billion annually in lost workplace productivity alone, with additional healthcare costs of $2,000 to $3,000 per patient per year compared to those without insomnia. Despite its prevalence, insomnia remains underdiagnosed and undertreated. The ISI evaluates seven dimensions of insomnia on a 0-to-4 severity scale: difficulty falling asleep (sleep onset latency), difficulty staying asleep (sleep maintenance), early morning awakening, satisfaction with current sleep pattern, interference with daily functioning, noticeability of sleep impairment to others, and worry or distress about the sleep problem. The total score ranges from 0 to 28 and maps to four severity categories that guide clinical decision-making. The ISI has been validated against polysomnography (PSG), the gold-standard objective sleep measurement, showing moderate correlations (r = 0.32 to 0.55 depending on the PSG parameter). It is more strongly correlated with subjective sleep diary measures (r = 0.65 to 0.80), reflecting the fact that insomnia is fundamentally a subjective complaint even when objective sleep parameters are within normal limits. The ISI is the primary outcome measure in virtually all cognitive-behavioral therapy for insomnia (CBT-I) trials and is used by sleep clinics, primary care providers, behavioral health specialists, and researchers worldwide.
ISI Total Score = sum of 7 items (each scored 0-4) Severity Classification: 0-7: No clinically significant insomnia 8-14: Subthreshold (mild) insomnia 15-21: Clinical (moderate) insomnia 22-28: Clinical (severe) insomnia Clinically meaningful change: reduction of 6 or more points Treatment response: ISI reduction >= 8 points Remission: post-treatment ISI < 8 Worked Example: Item 1 (difficulty falling asleep): 3 (severe) Item 2 (difficulty staying asleep): 2 (moderate) Item 3 (early awakening): 1 (mild) Item 4 (sleep satisfaction): 3 (very dissatisfied) Item 5 (daytime impairment): 3 (much interference) Item 6 (noticeability): 2 (somewhat noticeable) Item 7 (worry about sleep): 3 (much worried) Total: 17 = Moderate clinical insomnia
- 1Complete all seven items based on your sleep experience over the past two weeks. The first three items assess the three types of insomnia complaints: difficulty falling asleep at bedtime (sleep onset insomnia), difficulty staying asleep during the night (sleep maintenance insomnia), and waking up too early in the morning and being unable to return to sleep (early morning awakening insomnia). Each is rated from 0 (none) to 4 (very severe). These items capture the core symptom presentation and help differentiate between insomnia subtypes that may respond differently to specific interventions.
- 2Rate your satisfaction with your current sleep pattern on item 4, from 0 (very satisfied) to 4 (very dissatisfied). This item captures the subjective quality component of insomnia, which may differ from the objective frequency of sleep disturbances. Some individuals with objectively mild sleep disruption experience severe dissatisfaction, while others with significant measurable disruption report adequate satisfaction. The discrepancy between objective and subjective assessment is a key feature of insomnia and an important treatment target.
- 3Assess the impact of your sleep problems on daily functioning on item 5, rating how much your sleep difficulties interfere with daytime functioning (fatigue, concentration, mood, productivity) from 0 (not at all interfering) to 4 (very much interfering). This item is critical for clinical diagnosis because the DSM-5 diagnostic criteria for Insomnia Disorder require clinically significant distress or impairment in social, occupational, or other important areas of functioning. A score of 3 or 4 on this item alone may justify clinical intervention.
- 4Evaluate the noticeability of your sleep impairment on item 6, rating how noticeable to others your sleep problem appears in terms of impairing your quality of life, from 0 (not at all noticeable) to 4 (very much noticeable). This external validation item helps calibrate self-perception against observable impact. Individuals who score high on this item are typically experiencing significant functional impairment that extends beyond their own awareness.
- 5Rate your level of worry or distress about your sleep on item 7, from 0 (not at all worried) to 4 (very much worried). This item captures the cognitive-emotional component of insomnia, which is often the primary maintenance factor in chronic insomnia. Excessive worry about sleep creates a paradoxical arousal state that perpetuates the very insomnia it attempts to address. This cognitive hyperarousal is the primary target of CBT-I, the first-line treatment for chronic insomnia.
- 6Sum all seven item scores to obtain the ISI total score (range 0-28). The calculator automatically classifies the total into one of four severity categories based on validated cutoffs: 0-7 (no clinically significant insomnia), 8-14 (subthreshold or mild insomnia), 15-21 (moderate clinical insomnia), and 22-28 (severe clinical insomnia). Scores of 15 or above indicate clinically significant insomnia that warrants treatment, with CBT-I as the recommended first-line intervention per American Academy of Sleep Medicine guidelines.
- 7Review the treatment recommendations based on your severity classification. For subthreshold insomnia (8-14), sleep hygiene education and stimulus control may be sufficient. For moderate insomnia (15-21), structured CBT-I (typically 6-8 sessions) is strongly recommended and is more effective than medication for long-term outcomes. For severe insomnia (22-28), combined CBT-I and short-term pharmacotherapy may be appropriate, with a plan to taper medication as CBT-I skills are established. The calculator provides referral information for CBT-I providers (CBTI Directory, VA CBT-I Coach app) and contextualizes the score against population norms.
This individual primary complaint is severe difficulty falling asleep (item 1 = 4) with significant worry about sleep (item 4 = 4), suggesting cognitive hyperarousal at bedtime. Sleep maintenance and early awakening are minimal concerns. The ISI total of 17 falls in the moderate clinical range and strongly predicts benefit from CBT-I, particularly the stimulus control and cognitive restructuring components. Sleep onset insomnia with high sleep-related worry typically responds well to treatment, with expected ISI reductions of 8-12 points over 6-8 sessions of CBT-I.
This individual experiences all three types of insomnia symptoms at severe levels, with maximum dissatisfaction and functional impairment. The ISI total of 23 is in the severe range. The uniform elevation across all items suggests possible comorbid conditions (depression, anxiety, chronic pain, sleep apnea) that should be evaluated before beginning insomnia-specific treatment. A sleep study (polysomnography) may be warranted to rule out obstructive sleep apnea, particularly if the patient reports snoring or witnessed apneas.
After completing 8 sessions of CBT-I, this individual ISI decreased from a pre-treatment score of 19 to a post-treatment score of 5, a reduction of 14 points that exceeds both the clinically meaningful change threshold (6 points) and the treatment response threshold (8 points). The post-treatment score below 8 meets the criterion for insomnia remission. Residual mild difficulty with sleep onset and slight dissatisfaction are within normal range and expected even after successful treatment.
Sleep medicine clinics use the ISI as a standard intake and outcome measure for all insomnia patients. The brevity of the seven-item questionnaire (under 5 minutes to complete) makes it practical for routine clinical use, and its validated severity cutoffs guide treatment intensity decisions. Most sleep clinics track ISI scores across treatment episodes using electronic health record integrations.
CBT-I therapists administer the ISI at every other session (biweekly) to monitor treatment progress and adjust interventions accordingly. The session-by-session ISI trajectory has been shown to predict eventual treatment outcome: patients who show at least a 4-point reduction by session 3 are significantly more likely to achieve remission by treatment completion. This early response pattern guides therapists in maintaining or modifying their treatment approach.
Pharmaceutical companies conducting clinical trials for insomnia medications use the ISI as a co-primary or secondary outcome measure alongside polysomnographic endpoints. The FDA has accepted the ISI as a patient-reported outcome (PRO) measure in insomnia drug development, and most recent approvals (suvorexant, lemborexant, daridorexant) included ISI data in their labeling. The clinically meaningful change threshold of 6 points has been used to define treatment responders in registration trials.
Primary care physicians use the ISI to screen for insomnia during annual wellness visits and to monitor patients who report sleep complaints. The seven-item format can be completed in the waiting room and scored immediately, enabling efficient integration into primary care workflows. Scores of 15 or above trigger referral to a behavioral sleep medicine specialist for CBT-I, which is recommended over medication as the first-line treatment by both the American College of Physicians and the American Academy of Sleep Medicine.
Individuals with comorbid depression and insomnia may show elevated ISI scores
Individuals with comorbid depression and insomnia may show elevated ISI scores that partially reflect depressive symptomatology rather than primary insomnia. Early morning awakening (item 3) is a hallmark of melancholic depression, and decreased sleep satisfaction (item 4) may reflect general anhedonia. In these cases, concurrent assessment with a depression measure (PHQ-9) helps determine whether insomnia is primary, comorbid, or secondary to depression. Current evidence supports treating both conditions simultaneously rather than waiting for depression treatment to resolve insomnia.
Shift workers face a unique challenge with the ISI because their insomnia may
Shift workers face a unique challenge with the ISI because their insomnia may be caused by circadian rhythm disruption (Shift Work Sleep Disorder) rather than primary insomnia. The ISI validly measures the severity of the symptom experience but does not distinguish between these etiologies. Shift workers with high ISI scores should be evaluated for circadian rhythm sleep-wake disorders, and treatment should address the circadian component (strategic light exposure, melatonin timing) in addition to behavioral insomnia strategies.
Older adults (age 65 and above) commonly report ISI scores in the mild range
Older adults (age 65 and above) commonly report ISI scores in the mild range (8-14) that may reflect normal age-related changes in sleep architecture rather than pathological insomnia. Sleep efficiency naturally decreases with age, and total sleep time shortens from approximately 7.5 hours in young adults to 6.5 hours in older adults. The clinical significance of mild ISI scores in older adults should be evaluated in the context of daytime functioning rather than sleep parameters alone.
| Score Range | Classification | Prevalence (Adults) | Recommended Intervention |
|---|---|---|---|
| 0-7 | No clinical insomnia | ~70% | No treatment needed; sleep hygiene education if desired |
| 8-14 | Subthreshold (mild) | ~15% | Sleep hygiene + stimulus control; monitor for worsening |
| 15-21 | Moderate clinical insomnia | ~10% | CBT-I (6-8 sessions); consider combined with short-term medication |
| 22-28 | Severe clinical insomnia | ~5% | Combined CBT-I + medication; evaluate for comorbidities |
What is a normal ISI score?
Scores of 0 to 7 are classified as no clinically significant insomnia. Community studies of adults without sleep complaints show mean ISI scores of approximately 3 to 5, with a standard deviation of about 4. Scores of 8 to 14 represent subthreshold or mild insomnia that may not require formal treatment but could benefit from sleep hygiene education.
What is CBT-I and why is it recommended over medication?
Cognitive-Behavioral Therapy for Insomnia is a structured psychological treatment that addresses the behavioral and cognitive factors maintaining chronic insomnia. Core components include stimulus control, sleep restriction therapy, cognitive restructuring, sleep hygiene education, and relaxation training, typically delivered in 6 to 8 sessions. CBT-I is recommended as the first-line treatment because it produces equivalent short-term improvement to medication with superior long-term outcomes, no risk of dependence, and sustained benefit after treatment completion.
Can the ISI detect sleep apnea?
No. The ISI measures subjective insomnia symptoms and does not detect obstructive sleep apnea (OSA), which requires polysomnography or home sleep testing for diagnosis. However, insomnia and OSA frequently co-occur (comorbid insomnia and sleep apnea, or COMISA, affects an estimated 30 to 50 percent of insomnia patients). A high ISI score accompanied by loud snoring, witnessed breathing pauses, morning headaches, or unexplained daytime sleepiness should prompt evaluation for sleep apnea before beginning insomnia-specific treatment.
How quickly should the ISI improve with treatment?
In CBT-I trials, the average ISI reduction is 8 to 12 points over 6 to 8 weeks of treatment. Most improvement occurs in the first 4 weeks, with continued smaller gains through the remainder of treatment. Approximately 60 to 80 percent of patients achieve clinically meaningful improvement (6 or more point reduction), and 40 to 60 percent achieve remission (ISI below 8). Medication trials show similar acute reductions but less sustained improvement after discontinuation.
Should I stop medications before taking the ISI?
The ISI should be completed based on your current sleep experience, including any effects of medications you are taking. If you are taking sleep medication, your ISI score reflects medicated sleep quality and may be lower than your untreated severity. This is useful for monitoring medication effectiveness but does not reveal underlying insomnia severity. If the goal is to assess insomnia severity independent of medication, a gradual medication taper under medical supervision followed by a drug-free ISI assessment provides the most accurate picture.
プロのヒント
If your ISI score is 15 or above, the most evidence-supported next step is not a sleeping pill but rather a course of CBT-I. The VA CBT-I Coach app (free, available on iOS and Android) provides guided self-help based on CBT-I principles and can reduce ISI scores by 5 to 8 points even without therapist contact. For more structured treatment, the CBTI Directory (cbtiirectory.com) maintains a searchable database of trained CBT-I providers. Many CBT-I programs are now available via telehealth, removing geographic barriers to accessing this gold-standard treatment.
ご存知でしたか？
The ISI was developed by Charles Morin at Universite Laval in Quebec, Canada, who is considered the most influential researcher in the field of insomnia treatment. His landmark 1999 randomized controlled trial demonstrating that CBT-I produces sustained improvement lasting three years (while medication effects wane after discontinuation) fundamentally changed the treatment hierarchy for insomnia. The ISI has been cited in over 6,000 peer-reviewed publications and translated into more than 40 languages, making it the single most widely used insomnia assessment instrument globally.